Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?

　　1.Can Sotorasib Achieve a Complete Cure?

　　Sotorasib cannot currently be regarded as a curative therapy.Clinical trial data show a median progression-free survival of approximately 6 to 7 months,an objective response rate of around 37%,and a median duration of response of about 11 months.While some patients experience meaningful and relatively durable tumor shrinkage,the complete response rate remains low,and most patients eventually develop acquired resistance leading to disease progression.A more accurate characterization is that sotorasib is an effective precision-targeted treatment that significantly delays disease progression,extends survival,and improves quality of life,rather than a one-time cure.Patients should discuss realistic expectations with their treating oncologist.

　　2.Approved Indications of Sotorasib

　　Sotorasib carries two primary approved indications.The first is as monotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer(NSCLC)harboring a confirmed KRAS G12C mutation who have received at least one prior systemic therapy.The second is in combination with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer who have previously been treated with fluoropyrimidine-,oxaliplatin-,and irinotecan-based chemotherapy.In all cases,confirmation of the KRAS G12C mutation through an approved diagnostic test is mandatory before initiating treatment.

　　3.How Sotorasib Works–A Plain-Language Explanation

　　The KRAS protein acts as a molecular"on-off switch"inside cells,regulating growth and division signals.When the KRAS gene acquires a G12C mutation(glycine at position 12 is replaced by cysteine),this switch becomes permanently stuck in the"on"position,continuously driving uncontrolled cell proliferation.Sotorasib is designed to form an irreversible covalent bond with the unique cysteine residue of the mutant KRAS G12C protein,locking it in the inactive GDP-bound state.In simple terms,it acts like a custom-fitted plug that forcibly turns the stuck switch off,thereby blocking downstream oncogenic signaling pathways such as MAPK and halting tumor growth.Because this binding site exists only on the mutant protein,sotorasib spares normal wild-type KRAS,demonstrating high selectivity.

　　4.Safety and Monitoring Considerations

　　Common adverse effects of sotorasib include diarrhea,elevated liver enzymes(ALT/AST),nausea,vomiting,and musculoskeletal pain.Regular monitoring of liver function is recommended throughout treatment.If grade 3 or higher diarrhea occurs,or if liver enzymes rise to more than five times the upper limit of normal,treatment should be interrupted and resumed at a reduced dose upon recovery.The standard dosing regimen is 960 mg taken orally once daily as a whole tablet;the tablet must not be split,crushed,or chewed.Patients should promptly report any adverse symptoms to their treating physician and should never adjust the dose or discontinue therapy without medical guidance.